Wesley Sundquist, a biochemist at the University of Utah, was recently featured in Time's annual "100 Most Influential People ...

The HIV treatment landscape has further evolved with the introduction of LAI therapies, offering alternatives to daily oral ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating lenacapavir, a long-lasting HIV prevention and treatment drug.

Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.

The trial will offer participants a new, twice-yearly injectable PrEP (pre-exposure prophylaxis) medicine called Lenacapivir.

A University of Utah biochemist found himself on Time Magazine's 100 most influential people of 2025 list alongside names ...

Biotech bigwig Gilead Sciences, Inc. GILD is scheduled to report first-quarter 2025 results on April 24, after market close.

The EU and other Western governments need to step up their funding commitments to AIDS programmes or risk a reversal of ...